Evicenter
P&T meetings

QTORIN rapamycin 3.9 percent gel

Microcystic lymphatic malformations

Regulatory submission
NDA submitted August 2026
Last updated
78 sources

Product information and disease descriptionProduct description

Product information

18 evidence topics · 12 sources

Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions

Not applicable.

Drug/Drug, drug/disease interactions
Effects of other drugs on sirolimus

No evidence found.

Effects of sirolimus on other drugs

No evidence found.

Co-prescribed/Concomitant therapies

No evidence found.

Effect of sirolimus on quality measures

No evidence found.

Product comparison

No evidence found.